Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

Background: The precise relationship between atrial fibrillation (AF), which affects a significant number of individuals, and heart failure (HF) remains poorly understood. With over 12 million projected cases of AF and 8 million of HF in the United States by 2030, the need for clarity led us to conduct the first-ever umbrella review, aiming to understand the inconsistent findings regarding the efficacy of catheter ablation (CA) versus medical therapy (MT) in this population.Methods: A comprehensive search was conducted across PubMed, Cochrane Library, and Google Scholar to identify relevant studies for inclusion in this umbrella review. The GRADE method was utilized to assess the overall certainty of the evidence thoroughly. Furthermore, the quality of the included reviews was carefully evaluated using the AMSTAR 2 and Cochrane Collaboration risk of bias tool.Results:  After careful review, six systematic reviews and meta-analyses were selected for analysis. Notably, Catheter ablation (CA) was associated with a significant reduction in all-cause mortality (RR [95% CI]: 0.55 [0.44, 0.68], I2: 60%, p-value: <0.00001), and Heart failure (HF) hospitalization risk (RR [95% CI]: 0.61 [0.54, 0.70], I2: 0%, p-value: <0.00001), as well as a decrease in atrial fibrillation (AF) recurrence rates (RR [95% CI]: 0.36 [0.27, 0.47], I2: 0%, p-value: <0.00001). Secondary efficacy outcomes, including changes in cardiac function parameters, favored CA over MT, with significant improvements observed in Left ventricular ejection fraction (LVEF) and 6-minute walk test (6MWT).Conclusion: AF and HF patients who received CA instead of MT had better functional outcomes and safety. The CA group has significantly lower all-cause mortality, HF hospitalization, AF recurrence, and LVEF, 6MWT, and VO2 max improvements than the MT group. Future research should include all participants with HF and AF to obtain a complete analysis.
Background and Aims: Finerenone, a nonsteroidal MR antagonist (MRA), enhances renal and cardiovascular outcomes in patients with type 2 diabetes (T2DM). Finerenone’s safety and effectiveness in renal function are debatable. This meta-analysis evaluates the efficacy and safety of treatments for patients with diabetic kidney disease.Methods: To find relevant RCTs, the databases PubMed, Embase, and Google Scholar were searched. Finerenone’s effects were quantified using estimated pooled mean differences (MDs) and relative risks with 95% confidence intervals (CIs).Results: This meta-analysis combines seven double-blind trials involving patients with CKD and type 2 diabetes who were randomly assigned to finerenone or placebo. The primary efficacy time-to-event outcomes were cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, heart failure hospitalization, kidney failure, a sustained 57% decrease in estimated glomerular filtration rate from baseline over 4 weeks, or renal death. In this meta-analysis of 39,995 patients, treatment with Finerenone was associated with a lower risk of death due to cardiovascular and renal outcomes than placebo (RR = 0.86 [0.80, 0.93] p=0.0002; I2= 0%) and (RR = 0.56 [0.17, 1.82] p=0.34; I2= 0%), respectively. Finerenone treatment was also associated with a marginally lower risk of serious adverse events (RR = 0.95 [0.92, 0.97] p 0.0001; I2= 0%), but no overall difference in the risk of adverse events was found between the two groups (RR = 1.00 [0.99, 1.01] p=0.56; I2= 0%).Conclusion: The administration of finerenone decreases the likelihood of end-stage kidney disease, renal failure, cardiovascular death, and hospitalization. Therefore, we propose that patients with T2DM and CKD undergo finerenone therapy.Keywords: Diabetes, Chronic kidney disease, CKD, Cardiovascular disease, Finerenone, Non-steroidal Mineralocorticoid receptor antagonist, Meta-analysis.